Neurocrine Biosciences Inc Dossier
Qualitative Analysis
Business overview
Neurocrine Biosciences, Inc. (NBIX) is a leading biopharmaceutical company dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric, and immunological disorders. For over three decades, the company has applied its unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. Its diverse commercial portfolio is anchored by INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington's disease, and CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia (CAH). Additionally, the company maintains a robust clinical pipeline of drug candidates across its core therapeutic areas, including small molecules, peptides, proteins, and gene therapies.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the commercial organization and sales teams to drive market penetration and patient adoption for flagship product INGREZZA and newly launched CRENESSITY [1.4.4].
Expected impact: Reaffirmation of INGREZZA sales guidance of $2.7 billion to $2.8 billion and rapid scaling of CRENESSITY.
Strategic expansion of the corticotropin-releasing factor (CRF) platform to target metabolic diseases, including obesity, led by the development of NBIP-2118 (a CRF2 agonist).
Expected impact: Establishes a new class of metabolic medicines to address the global obesity epidemic.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Soleno Therapeutics, Inc. to obtain VYKAT XR, a once-daily tablet for Prader-Willi syndrome.
Financial impact: Adds a high-growth commercial asset that generated $190 million in 2025 revenue and is expected to deliver long-term value with IP extending into the mid-2040s.
Strategic Partnerships
Divestiture of Neurocrine Group Limited (formerly Diurnal Group) to focus on core US commercial operations and pipeline development.
Terms: Immedica acquired the entity for $65 million in cash, which closed in January 2026.